January 7, 2020 Life Science Tools M&A, Partnerships

ERS Genomics announces agreement with New England Biolabs to commercialize CRISPR gene editing tools and reagents

License agreement expands New England Biolabs’ rights to use and sell CRISPR/Cas9 reagents and tools DUBLIN, Ireland, and Ipswich MA, USA, (07 January 2020): ERS Genomics Limited, which was formed to provide broad access to the foundational CRISPR/Cas9 intellectual property (IP) co-owned by Dr. Emmanuelle Charpentier, today announced it has signed an agreement with New England Biolabs... Read more

November 1, 2018 Licensing, IP, and Legal Life Science Tools

ERS Genomics Licenses CRISPR Gene Editing Technology to DefiniGEN to Develop Human Cell Models to Support the Preclinical Development of Therapeutics

DUBLIN, Ireland, and CAMBRIDGE, UK, November 01, 2018 – ERS Genomics Limited and DefiniGEN Ltd announced today a license agreement to provide DefiniGEN with access to ERS Genomic’s CRISPR/Cas9 genome editing technology patents. DefiniGEN will combine their best-in-class iPSC (induced Pluripotent Stem Cell) differentiation platform with CRISPR/Cas9 technology to generate a range of innovative preclinical... Read more

November 10, 2017 Licensing, IP, and Legal Life Science Tools

ERS Genomics and Cellecta, Inc. Sign License Agreement on CRISPR/Cas9 Genome Editing Patents for Tools and Services

DUBLIN, Ireland, and Mountain View, CA, November 10, 2017 – ERS Genomics Ltd. and Cellecta, Inc. announced today a non-exclusive license agreement to provide Cellecta with worldwide access to ERS Genomics’ CRISPR/Cas9 genome editing intellectual property for use in informing research tools and services. ERS Genomics holds rights to the foundational CRISPR/Cas9 patent portfolio from Dr. Emmanuelle Charpentier, who... Read more